
John Mandrola
Host at This Week in Cardiology
Writer and Podcaster at Sensible Medicine Newsletter
Heart rhythm doc, writer for @Medscape, host of This Week in Cardiology podcast, cyclist, #MedicalConservative. The more you see, the harder medicine gets
Articles
-
5 days ago |
medscape.com | John Mandrola
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. My Alerts You have already selected for My Alerts Add Other Topics Click the topic below to receive emails when new articles are available. Add You've successfully added to your alerts. You will receive email when new content is published.
-
1 week ago |
medscape.com | John Mandrola
What happened with the 5-year FAME 3 results is not right. The reporting of this trial comparing stenting vs coronary artery bypass graft surgery (CABG) in patients with multivessel coronary artery disease (CAD) defies proper scientific principles. FAME 3 tested the best strategy to revascularize patients with multivessel CAD. Three previous trials comparing percutaneous coronary intervention (PCI) vs CABG (SYNTAX, FREEDOM, and BEST) had all found surgery to be superior.
-
1 week ago |
sensible-med.com | John Mandrola
This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts
-
1 week ago |
sensible-med.com | John Mandrola
I enjoyed reading the comments on yesterday's post regarding the positive results of the ESSENCE trial of semaglutide vs placebo in patients with metabolic dysfunction-associated steatohepatitis (MASH). Thank you to those who took the time to write. I wanted to share some very brief thoughts on two basic tenets of medical practice that emerged from the thoughtful commentary. This Substack remains free of industry support due to the generosity of our readers.
-
1 week ago |
sensible-med.com | John Mandrola
Three professors, writing in the Lancet, estimated that the global prevalence of the condition is 25%. A modeling study predicted that its prevalence will rise sharply in the coming decade. The condition has a terrible name. It’s called metabolic dysfunction-associated steatohepatitis (MASH). That’s its new name. The old names, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) were not much better.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 66K
- Tweets
- 29K
- DMs Open
- No

RT @FrobertOle: Published a letter in @TheEconomist @mmamas1973 @SVRaoMD @cpgale3 @DavidLBrownMD @drjohnm @Lpa_Doc @NielsRHolm https://t.c…

RT @sfmcguire79: Harvard has seen a surge in donations since standing up to Trump. But the total received so far is only $1.14 million, wh…

Good question and interesting paper. 👇🏻 My 2 cents, Lp (a) is a marker more than a causal agent. I predict w low levels of conviction that Lp (a) lowering trials will be meh

Lp(a) levels not associated with cardiovascular or all cause death when LDL and CRP adjusted for. Is Lp(a) just a marker of risk or is it causal ? https://t.co/77kRFHZNiF https://t.co/sd6FQ6MgIh